Genetic susceptibility to thrombotic microangiopathy in a 10-month-old patient with SMA type 1: a caveat for gene therapy eligibility.

D'Alessandro R, Somà A, Vacchetti M, Salvalaggio A, Guarnone E, Cavallina I, Rolle E, Rossi F, Montin D, Saglio F, Peruzzi L, Barberis M, Sbaiz L, Deaglio S, Fagioli F, Mongini TE, Ricci FS

Open source

DOI
10.1016/j.nmd.2026.107376
Published
2026 Sep
Container
Neuromuscular disorders : NMD
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.nmd.2026.107376,
  title = {Genetic susceptibility to thrombotic microangiopathy in a 10-month-old patient with SMA type 1: a caveat for gene therapy eligibility.},
  author = {D'Alessandro R and Somà A and Vacchetti M and Salvalaggio A and Guarnone E and Cavallina I and Rolle E and Rossi F and Montin D and Saglio F and Peruzzi L and Barberis M and Sbaiz L and Deaglio S and Fagioli F and Mongini TE and Ricci FS},
  year = {2026},
  journal = {Neuromuscular disorders : NMD},
  doi = {10.1016/j.nmd.2026.107376},
  url = {https://doi.org/10.1016/j.nmd.2026.107376}
}

RIS

TY  - JOUR
TI  - Genetic susceptibility to thrombotic microangiopathy in a 10-month-old patient with SMA type 1: a caveat for gene therapy eligibility.
AU  - D'Alessandro R
AU  - Somà A
AU  - Vacchetti M
AU  - Salvalaggio A
AU  - Guarnone E
AU  - Cavallina I
AU  - Rolle E
AU  - Rossi F
AU  - Montin D
AU  - Saglio F
AU  - Peruzzi L
AU  - Barberis M
AU  - Sbaiz L
AU  - Deaglio S
AU  - Fagioli F
AU  - Mongini TE
AU  - Ricci FS
PY  - 2026
JO  - Neuromuscular disorders : NMD
DO  - 10.1016/j.nmd.2026.107376
UR  - https://doi.org/10.1016/j.nmd.2026.107376
ER  - 

APA

R, D., A, S., M, V., A, S., E, G., I, C., E, R., F, R., D, M., F, S., L, P., M, B., L, S., S, D., F, F., TE, M., & FS, R. (2026). Genetic susceptibility to thrombotic microangiopathy in a 10-month-old patient with SMA type 1: a caveat for gene therapy eligibility.. Neuromuscular disorders : NMD. https://doi.org/10.1016/j.nmd.2026.107376

Source records